According to a new report published by Introspective Market Research, titled, “Gene Panel Market by Type, Application, and End User,” The Global Gene Panel Market Size Was Valued at USD 2.98 Billion in 2023 and is Projected to Reach USD 13.12 Billion by 2032, Growing at a CAGR of 17.9%.

2. Introduction / Market Overview

The global Gene Panel Market is witnessing remarkable growth as precision medicine, genetic diagnostics, and next-generation sequencing technologies continue to revolutionize healthcare. Gene panels, which allow simultaneous analysis of multiple genes associated with specific diseases or conditions, have become indispensable tools in clinical diagnostics, oncology, and pharmacogenomics. These panels help identify genetic mutations and hereditary conditions, supporting timely diagnosis and effective treatment planning.

Unlike traditional single-gene testing methods, gene panels offer cost-effectiveness, faster turnaround time, and comprehensive genetic insights. Their adoption is expanding rapidly across clinical laboratories, hospitals, and research centers, driven by growing awareness of genetic diseases and the increasing demand for personalized medicine. Additionally, advancements in sequencing technologies and bioinformatics tools have further enhanced the accuracy and reliability of gene panel testing, making it a cornerstone of modern genomics.

3. Market Segmentation

The Gene Panel Market is segmented into Type, Application, and End User.

• By Type, the market is categorized into (Small Panels, Large Panels).
• By Application, the market is categorized into (Cancer Risk Assessment, Pharmacogenetics, Diagnosis of Congenital Disorders, Others).
• By End User, the market is categorized into (Hospitals, Diagnostic Laboratories, Research and Academic Institutes).

4. Growth Driver

One of the key growth drivers of the Gene Panel Market is the rising prevalence of genetic disorders and cancers. With the global burden of hereditary and oncology-related conditions increasing, healthcare providers are turning toward genetic testing for early detection and precision treatment. The integration of next-generation sequencing (NGS) technologies into gene panels has improved analytical efficiency, enabling comprehensive mutation analysis in a single test. This trend is accelerating adoption, particularly in oncology diagnostics, where gene panels play a critical role in identifying actionable mutations for targeted therapies.

5. Market Opportunity

A major opportunity for market expansion lies in the integration of gene panel testing with artificial intelligence (AI) and bioinformatics. As genomic datasets become more complex, AI-driven tools can enhance data interpretation and accuracy in detecting disease-causing variants. This integration will significantly improve clinical decision-making and enable more personalized treatment options. Moreover, the increasing availability of direct-to-consumer genetic testing services and expanding reimbursement policies for genetic testing will further create lucrative opportunities for market players in the coming years.

6. Detailed Segmentation

Gene Panel Market, Segmentation

The Gene Panel Market is segmented on the basis of Type, Application, and End User.

Type
The Type segment is further classified into Small Panels and Large Panels. Among these, the Small Panels segment accounted for the highest market share in 2023. Small panels are preferred due to their cost efficiency, faster results, and clinical relevance in targeting specific gene sets associated with particular diseases. They are widely used in oncology diagnostics, enabling focused analysis of actionable genes, which streamlines clinical workflows and reduces interpretation complexity.

Application
The Application segment is further classified into Cancer Risk Assessment, Pharmacogenetics, Diagnosis of Congenital Disorders, and Others. Among these, the Cancer Risk Assessment segment accounted for the highest market share in 2023. The rising incidence of cancer and the growing importance of early genetic screening for hereditary cancers, such as breast and ovarian cancer, are key factors driving this dominance. Cancer-focused gene panels enable precise identification of pathogenic variants, improving personalized therapy outcomes and preventive care strategies.

7. Some of The Leading/Active Market Players Are-

• Illumina, Inc. (United States)
  • Thermo Fisher Scientific Inc. (United States)
  • Agilent Technologies, Inc. (United States)
  • QIAGEN N.V. (Netherlands)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • BGI Genomics Co., Ltd. (China)
  • Integrated DNA Technologies, Inc. (United States)
  • Eurofins Scientific (Luxembourg)
  • Personalis, Inc. (United States)
  • Invitae Corporation (United States)
  • Guardant Health, Inc. (United States)
  • ArcherDx, Inc. (United States)
  • Oxford Nanopore Technologies (United Kingdom)
  • GenScript Biotech Corporation (China)
  • Illumina TruSight (United States)
  and other active players.

8. Key Industry Developments

News 1: In April 2024, Thermo Fisher Scientific launched its Oncomine Dx Express Test, a next-generation sequencing-based gene panel for precision oncology. This development enhances comprehensive genomic profiling for solid tumors and hematologic malignancies, allowing clinicians to make faster and more accurate treatment decisions.

News 2: In January 2025, Illumina, Inc. announced a strategic collaboration with AstraZeneca to develop AI-driven gene panels for early cancer detection. The partnership aims to leverage Illumina’s sequencing expertise with AstraZeneca’s clinical insights to accelerate personalized medicine innovations globally.

9. Key Findings of the Study

• Small Panels dominated the market in 2023 due to faster and cost-effective testing.
  • Cancer Risk Assessment was the leading application segment.
  • North America held the largest market share owing to advanced healthcare infrastructure.
  • Rising prevalence of genetic disorders and precision medicine initiatives drive market growth.
  • AI integration in gene analysis presents major future opportunities.